Neutrophil-derived microRNAs put the (DNA) breaks on intestinal mucosal healing

Eóin N. McNamee


**Commentary**

A predominant feature of intestinal inflammation is the accumulation of neutrophils, which dictates a fine balance between epithelial repair or progression to chronic inflammation. While the processes of mucosal healing are well studied, how neutrophils advance an inflammatory insult towards epithelial neoplasia is less understood. In this issue of the *JCI*, Butin-Israeli et al. outline a mechanism whereby neutrophils control epithelial fitness and genomic instability via delivery of miR-23a–and miR-155–containing microparticles. Localized delivery of antisense oligonucleotides targeting miR-23a and miR-155 reversed this genomic instability and accelerated mucosal healing. This mechanism of neutrophil-derived microRNA shuttling opens up new therapeutic potential to enhance epithelial healing and limit mucosal injury.

Find the latest version:

http://jci.me/125779/pdf
Neutrophil-derived microRNAs put the (DNA) breaks on intestinal mucosal healing

Eóin N. McNamee

Mucosal Inflammation Program, School of Medicine, University of Colorado – Anschutz Medical Campus, Aurora, Colorado, USA. Institute of Immunology, Department of Biology, Maynooth University, County Kildare, Ireland.

A predominant feature of intestinal inflammation is the accumulation of neutrophils, which dictates a fine balance between epithelial repair or progression to chronic inflammation. While the processes of mucosal healing are well studied, how neutrophils advance an inflammatory insult towards epithelial neoplasia is less understood. In this issue of the JCI, Butin-Israeli et al. outline a mechanism whereby neutrophils control epithelial fitness and genomic instability via delivery of miR-23a– and miR-155–containing microparticles. Localized delivery of antisense oligonucleotides targeting miR-23a and miR-155 reversed this genomic instability and accelerated mucosal healing. This mechanism of neutrophil-derived microRNA shuttling opens up new therapeutic potential to enhance epithelial healing and limit mucosal injury.

Neutrophils control inflammation and mucosal healing

As the first immune cell recruited to sites of inflammation, neutrophils and their cargo are crucial for shaping mucosal responses to infection, injury, and repair. These cells play an essential role in clearing invasive microorganisms and, when not tightly regulated, can trigger feed-forward amplification loops that promote tissue damage and chronic disease (1). Neutrophils utilize soluble mediators, such as cytokines, and processes, including production and release of neutrophil extracellular traps (NETs), reactive oxygen species (ROS), elastases, myeloperoxidase (MPO), and matrix metalloproteinases (MMPs), to perform antimicrobial functions and perpetuate chronic inflammation. The importance of maintaining this fine balance is underscored in experimental mouse studies, which show that neutrophil depletion or inability to mount respiratory burst results in increased growth of commensal bacteria or catastrophic experimental colitis, respectively (2–4). In patients with ulcerative colitis (UC), however, neutrophil accumulation in the stool positively correlates with active disease, and neutrophil infiltration into colonic tissue associates with disease severity (5). Indeed, transepithelial migration of neutrophils into the lumen (crypt abscess) is a cardinal pathological hallmark of UC; therefore, fine-tuning neutrophil transepithelial migration has been proposed to facilitate the management of UC (6), while sparing antimicrobial immunity.

Linking neutrophilic inflammation to epithelial genomic instability

There is a long-standing clinical link between chronic UC and increased risk of developing colorectal cancer (CRC), with recent meta-analysis showing CRC incidence of approximately 5% over 20 years in patients with chronic UC (7, 8). A large Danish study with meta-analysis of a population-based cohort found much lower cumulative CRC risks for UC patients over a 30-year period (9), though subgroups of patients, including those with early onset diagnosis, longer disease duration, or secondary complications such as primary sclerosing cholangitis (PSC), were at increased risk of CRC. As such, understanding how episodes of active inflammation in the colonic mucosa impact epithelial health and genomic integrity remains critically important. A consensus understanding has been that chronic episodes of localized neutrophilic inflammation is a contributing factor, resulting in oxidative stress–induced DNA damage, oncogene activation, and tumor progression (10, 11). However, an exact mechanistic understanding of the processes driving CRC in UC patients remains to be determined.

In this issue, Butin-Israeli and colleagues advance this knowledge gap by identifying a potentially novel and unexpected mechanism, whereby transmigrating neutrophils promote the accumulation of double-strand DNA breaks (DSBs) in intestinal epithelial cells by shuttling microRNA-containing microparticles (12). Patients with active inflammatory bowel disease (IBD) exhibited a marked accumulation of DSBs in intestinal epithelial cells, with a concomitant decrease in nuclear integrity. Moreover, these alterations were accompanied by increased expression of MPO, elastase, and inflammatory cytokines, such as TNF, IL-6, and IFN-γ. Using a series of reductionist in vitro culture systems, including human colonic enteroids and in vivo models of biopsy-induced sterile injury, Butin-Israeli et al. demonstrate that neutrophil-derived microparticles can selectively induce downstream effects on DNA damage. Neutrophil-derived microparticles alone induced DNA damage response in proliferating epithelial cells, a response that was blocked following inhibition of microparticle uptake. A decrease in epithelial cell proliferation did not

Related Article: p. 712

Conflict of interest: The author has declared that no conflict of interest exists.
patients with active IBD and correlate with increased neutrophils, defective epithelial micronuclei, increased epithelial DNA damage, and decreased lamin B1. One of the greatest practical challenges in developing a proof-of-concept therapeutic modality to target these microRNAs is selective targeting to epithelial cells in the intestine. The authors overcame this hurdle by utilizing an elegant model of inflammation-independent wounding (needle biopsy with mouse colonoscopy) and delivered ASOs targeting miR-23a and miR-155 by site-directed microinjection 24 hours after injury (12). This approach substantially protected the wound site from DSBs and markedly increased expression of lamin B1 and RAD51, and enhanced epithelial restitution and the rate of wound closure (Figure 1).

MicroRNAs are small noncoding RNAs (~22 nucleotides) that regulate an array of cellular processes by inhibiting the translation of protein-coding mRNA transcripts. Functional microRNAs encapsulated within microparticles and microvesicles have been shown to shuttle into target cells in mucosal tissues during injury, inflammation, and infection (13–15); however, selectively targeting specific microRNAs in vivo to a defined cell type is technically very challenging (Figure 1).

**Targeting candidate microRNA for mucosal healing: no small task**

In addition to in vitro systems and murine models, Butin-Israel et al. demonstrated that expression of both miR-23a and miR-155 is increased in mucosal biopsies from patients with active IBD and correlate with increased neutrophils, defective epithelial micronuclei, increased epithelial DNA damage, and decreased lamin B1. One of the greatest practical challenges in developing a proof-of-concept therapeutic modality to target these microRNAs is selective targeting to epithelial cells in the intestine. The authors overcame this hurdle by utilizing an elegant model of inflammation-independent wounding (needle biopsy with mouse colonoscopy) and delivered ASOs targeting miR-23a and miR-155 by site-directed microinjection 24 hours after injury (12). This approach substantially protected the wound site from DSBs and markedly increased expression of lamin B1 and RAD51, and enhanced epithelial restitution and the rate of wound closure (Figure 1). It is worth noting that...
off-target effects of microRNA blockade could have profound long-term consequences for epithelial function. For example, miR-155 is known to repress hypoxia-inducible factor HIF-1α, which has a protective role in maintaining intestinal epithelial barrier integrity (16–18). Thus, blocking miR-23a and miR-155 with ASOs may impact other reparative gene expression profiles. In addition, it is not known how this approach works in the context of inflammation and microbiome dysbiosis, such as occurs during active flares in UC patients, and it may yield different results. However, it should be noted that antibody-mediated depletion of neutrophils had similar effects as ASO-mediated blockade of miR-23a and miR-155. Acute depletion of neutrophils in a dextran sulfate sodium–induced model of colitis reduced DSBs and reversed the imbalance of lamin B1 and RAD51. Thus, Butin-Israeli and colleagues also raises the question of whether all neutrophils (and neutrophil-derived microparticles) are created equally? That is to say, will multiple rounds of neutrophil hematopoiesis and consistent mucosal ulceration during active UC flares alter the fitness and function of microparticles? The stratification of neutrophils based on phenotype and function as pro-versus anti-cancer has been observed, and CRC can be stratified based on the composition of neutrophil and myeloid-derived suppressor cell (MDSC) infiltrates (19, 20). These phenotypic data are lacking, but warranted, for the continuum of chronic mucosal disease in UC; however, immune cell phenotypes are sure to be confounded by continuing responses to the commensal microbiota and UC-associated dysbiosis.

Mucosal healing and remission are emerging as the primary therapeutic goals for preventing CRC in UC patients (21, 22). The work by Butin-Israeli et al. raises the question of how treatment responses of UC patients to an armamentarium of current therapeutics might alter the identified neutrophil/microparticle/epithelial cell axis? Recent analysis has suggested that current therapies, such as 5-aminosalicylic acid (5-ASA) and thiopurine, have chemopreventive effects in UC (23, 24), but there is limited evidence on the effects of biologic therapy on the incidence of CRC for UC patients. To date, it is not known how these biotherapeutics impact microparticle and microRNA biology. As alluded to by Butin-Israeli and colleagues, the utility of future microRNA therapeutics will always be hampered by the technical challenges of cell-specific targeting and subverting the issue of multiple off-target mRNA candidates for each miRNA. However, by utilizing selective microRNAs as a prism to separate and underscore major disease pathways in vivo, elegant bodies of work such as the one by Butin-Israeli and colleagues can uncover master circuits driving disease in both IBD and CRC. While both microRNA and microparticle biology are relatively understudied, extensions of Butin-Israeli et al.’s work may identify drug-responsive therapeutic candidates for both IBD and CRC.

Acknowledgments
ENM is supported by grants from the Crohn’s and Colitis Foundation of America (409992) and the NIH National Institute of Diabetes and Digestive and Kidney Diseases (R01DK111856).

Address correspondence to: Eón N. McNamme, Institute of Immunology, Department of Biology, Maynooth University, County Kildare, Ireland. Phone: 353.1.708.6369; Email: eoin.n.mcnamme@mu.ie.
COMMENTARY


